论文部分内容阅读
目的研究胸腺肽α1(Tα1)对肝癌动脉插管化疗栓塞(TACE)患者T细胞亚群的影响。方法选取海南省农垦总局医院2009年2月~2010年5月间收治的TACE患者40例,随机分为治疗组与对照组各20例,治疗组于介入前4d每天皮下注射Tα11.6mg,对照组不采用Tα1治疗,分别用流式细胞仪计数患者CD3+,CD4+,CD4+/CD8+,NK细胞阳性百分率化疗前后的变化。结果治疗组CD3+,CD4+,CD4+/CD8+,NK细胞化疗后明显高于对照组,组间比较差异有统计学意义(P<0.05)。结论Tα1可以提高肝癌TACE患者免疫功能,减轻化疗副反应,其本身无显著副反应及不良反应,是一种安全可靠的免疫增强剂。
Objective To investigate the effect of thymosin α1 (Tα1) on T cell subsets in patients with hepatocellular carcinoma after arterial catheterization and chemoembolization (TACE). Methods Forty TACE patients admitted to Hainan Provincial Bureau of Land Reclamation from February 2009 to May 2010 were randomly divided into treatment group (n = 20) and control group (n = 20). The treatment group received subcutaneous injection of Tα11.6mg The patients were not treated with Tα1, and the changes of CD3 +, CD4 +, CD4 + / CD8 + and NK cells positive percentage before and after chemotherapy were counted by flow cytometry. Results The levels of CD3 +, CD4 +, CD4 + / CD8 + and NK cells in the treatment group were significantly higher than those in the control group after chemotherapy. There was significant difference between the two groups (P <0.05). Conclusion Tα1 can improve the immune function of TACE patients with hepatocellular carcinoma and reduce the side effects of chemotherapy. Tα1 itself has no obvious adverse reactions and side effects. It is a safe and reliable immune enhancer.